Pharma News

Nevro Corp and Boston Scientific Corp announced today that they have reached a settlement in their ongoing intellectual property litigations that gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, and gives Nevro the freedom to operate using the features and capabilities embodied in its current line of products.

Upadacitinib significantly improved the signs and symptoms of non-radiographic axial spondyloarthritis compared with placebo at week 14. Upadacitinib, sold under the brand name Rinvoq by Abbvie.

Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients with ankylosing spondylitis. Researchers aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.

Pfizer Inc and BioNTech SE announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.

The U.S. Food and Drug Administration prioritizes the health and safety of American consumers and patients as well as animals and uses a variety of tools for the appropriate oversight of FDA-regulated products and establishments. With manufacturers and supply chains dispersed around the world, the FDA works to help ensure that only products that meet our rigorous standards reach the U.S. marketplace.

Colorectal tumors are swarming with white blood cells, but whether these cells help or hinder the cancer is hotly debated. While some studies have shown that white blood cells heroically restrict tumor growth and combat colorectal cancer, equally compelling evidence casts the white blood cells as malignant co-conspirators bolstering the tumor and helping it spread.

Natco Pharma Limitedannounces that the U.S. Food and Drug Administration has granted approval to its partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) for the 60mg/1.5mL (40mg/mL) strength.

Cosmohome Tech Expo was held in Delhi at Pragati Maidan on 14th & 15th July 2022. Cosmohome Tech Expo is South Asia’s largest manufacturing trade show for the Cosmetic, Personal care, Cosmeceutical, Perfumery & Soap, detergent, and toiletries market. It is conceptualized on bringing the complete Innovative solutions to the beauty manufacturers right from the concept to formulation to technology to product launch for making the advancements in the manufacturing world.

The old Drugs and Cosmetics Act, 1940 is to be replaced by the New Drugs, Medical Devices and Cosmetics Bill, 2022. Ministry of Health and Family Welfare, Government of India proposes a draft New Drugs, Medical Devices and Cosmetics Bill, 2022 in order to keep pace with changing needs, times, technology.

Dr. Reddys Laboratories Ltd is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.